CBD254-012.pdf
PDF 47 KB Posted
- Solicitation number
- CBD254-012
About this file
This document is a Statement of Objectives (SOO) for a Defense Threat Reduction Agency (DTRA) research and development opportunity titled CBD254-012: Microphysiological Systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE). The objective is to develop an immune microphysiological system (iMPS)—including immune organoids, organ-tissue equivalents, microfluidic chips, or similar systems—capable of evaluating and developing vaccines against high consequence pathogens. The iMPS must model the human immune response in vitro to accelerate vaccine discovery and validation, addressing the disconnect between preclinical data and human clinical trials that currently hampers rapid response to emerging threats. No CMMC level requirement applies, and the technology areas include BioMedical and Chemical Biological Defense with Biotechnology as the modernization priority.
Phase I requires development or refinement of an iMPS demonstrating capability to recapitulate immunogenicity and efficacy of an FDA-approved vaccine against a viral pathogen, with standardized data outputs comparable to existing preclinical and clinical data. Phase II expands to forecasting performance of novel vaccine constructs through development of Standard Operating Procedures (SOPs), training materials, and standardized datasets. Phase III broadens application by evaluating route of administration, dose optimization, booster frequency, and off-target effects through multi-organ systems while reducing reliance on traditional animal models. The document notes Phase III dual-use applications enabling commercial biotechnology companies, pharmaceutical companies, academic research labs, and public health organizations to evaluate vaccine immunogenicity outside animal models in line with FDA guidance. No technical point of contact is listed.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| CBD_SBIR_25.4_R12.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
CBD254-012: Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)
PROJECTED CMMC LEVEL REQUIREMENT:
N/A
TECHNOLOGY AREAS:
Bio Medical | Chem Bio Defense
MODERNIZATION PRIORITIES:
Biotechnology
KEYWORDS:
Microphysiological system, New Alternative Methodologies, Medical Countermeasures, Vaccines, Immunogenicity
ADDITIONAL INFORMATION
N/A
OBJECTIVE:
Develop an immune microphysiological systems (iMPS) for the evaluation and development of vaccines against high consequence pathogens. iMPS may include, but are not limited to, immune organoid, organ-tissue equivalent, microfluidic chips, or similar systems as well as single or multiple organ models.
DESCRIPTION:
The Defense Threat Reduction Agency (DTRA) Research and Development Chemical and Biological Technologies Directorate Medical division in support of the Joint Science and Technology Office (JSTO) is charged with addressing the potential threat to the armed services posed by a wide range of pathogenic and toxic agents. In support of warfighter readiness, vaccines build a defense against known and future threats. However, the development of vaccines is stymied by traditional in vitro or in vivo models, which are slow and do not fully recapitulate the complexity of the human immune system. As a result, promising preclinical data do not necessarily translate to successful human clinical trials. This disconnect inhibits rapid response against new and emerging threats to the Warfighter.
iMPS have the potential to model the human immune response in vitro, providing a route to accelerated discovery and validation of medical countermeasures by offering a bridge between preclinical studies and advanced development. Successful iMPS should (1) recapitulate immunogenicity and efficacy of a known vaccine, (2) differentiate between vaccines with variable efficacy against the same threat, and (3) predict immunogenicity of novel vaccine constructs. It would also be beneficial if iMPS could evaluate the optimal vaccine dose, schedule, and route of administration as well as predict off-target effects of a vaccine. Additionally, the data output of ideal iMPS should be standardized so that they may be compared to existing animal models and/or clinical data.
Eventually, iMPS would be utilized to assess vaccine immunogenicity and efficacy against DoD pathogens of concern in a high containment environment and ultimately, would greatly facilitate vaccine development and support Warfighter readiness.
PHASE I:
The objective of Phase I is to develop an iMPS or refine an existing iMPS and demonstrate that it is capable of recapitulating the immunogenicity and efficacy of an FDA-approved vaccine against a viral pathogen. The iMPS should be capable of key functions of the innate and adaptive immune systems and data outputs should be standardized to enable comparison to existing preclinical and clinical data. Success will be measured by comparing the iMPS-produced data to existing clinical data. This phase aims to establish the foundational validity of the iMPS as a reliable tool for vaccine evaluation.
PHASE II:
Phase II moves beyond replicating known vaccine responses to actively forecasting the performance of new vaccines before in vivo studies or clinical trials. It will leverage the iMPS developed or refined in Phase I to predict the immunogenicity and efficacy of novel vaccine constructs against pathogens of concern for the DoD. When available, iMPS-produced data should be compared to preclinical in vitro or in vivo data. To ensure the reproducibility and consistency of results across different laboratories and users, Standard Operating Procedures (SOPs) for the operation and maintenance of the iMPS should be developed and if necessary for the operation of the iMPS, comprehensive training materials should also be created. Deliverables will be iMPS SOPs and training materials as well as standardized datasets and summary reports on each vaccine construct tested.
PHASE III DUAL USE APPLICATIONS:
PHASE III: This phase focuses on broadening the iMPS's application in vaccine development. Key parameters, such as route of administration, dose optimization, and booster frequency, will be evaluated using the iMPS.
Furthermore, the iMPS will be utilized in a multi-organ MPS to assess potential off-target effects of vaccine candidates. The goal is to create a comprehensive iMPS platform capable of informing critical decisions throughout the vaccine development pipeline, reducing reliance on traditional animal models, and accelerating the path to clinical trials PHASE III DUAL USE APPLICATIONS: Beyond DoD applications, the iMPS developed may be used by commercial biotechnology companies, pharmaceutical companies, academic research labs, and public health organizations to evaluate vaccine immunogenicity and efficacy outside of an animal model, in line with FDA guidance.
REFERENCES:
Morrocchi E, van Haren S, Palma P, Levy O. Modeling human immune responses to vaccination in vitro.
Trends Immunol. 2024 Jan.,45(1):32-47. doi: 10.1016/j.it.2023.11.002. Epub 2023 Dec 21. PMID: 38135599., PMCID: PMC11688643.
1.
TECHNICAL POINT OF CONTACT (TPOC):
None
File details come from the government source that posted it. Updated .